announces

CoinW Announces 4 Block Sponsorship at Consensus Hong Kong 2025CoinW Announces 4 Block Sponsorship at Consensus Hong Kong 2025

CoinW Announces 4 Block Sponsorship at Consensus Hong Kong 2025

HONG KONG, Feb. 13, 2025 /PRNewswire/ -- CoinW, a leading global cryptocurrency exchange, is set to make a bold statement…

8 hours ago
Altair Announces Future.Industry 2025 Global EventAltair Announces Future.Industry 2025 Global Event

Altair Announces Future.Industry 2025 Global Event

Virtual event will bring together thought leaders, industry experts, and visionaries to explore how technology is transforming the ways we…

1 day ago
Nxu Announces Shareholder Approval of Merger with Verde BioresinsNxu Announces Shareholder Approval of Merger with Verde Bioresins

Nxu Announces Shareholder Approval of Merger with Verde Bioresins

MESA, Ariz., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Nxu, Inc., (NASDAQ: NXU) (“Nxu”, “the Company”), a domestic technology company focused…

1 day ago
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNUPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

2 days ago
Lighthouse Autism Center Announces Expansion of ABA Services in NebraskaLighthouse Autism Center Announces Expansion of ABA Services in Nebraska

Lighthouse Autism Center Announces Expansion of ABA Services in Nebraska

Leading ABA Provider Set to Open Newest Location in Lincoln, NE. February 11, 2025 20:00 ET  | Source: Lighthouse Autism…

2 days ago
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNSpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

2 days ago
Manulife Asia Announces Senior Leadership Team ChangesManulife Asia Announces Senior Leadership Team Changes

Manulife Asia Announces Senior Leadership Team Changes

Changes Include Emerging Markets, Indonesia, Japan, Singapore and Finance HONG KONG, February 10, 2025 /PRNewswire/ -- Manulife Asia has announced strategic…

3 days ago
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs HoldersGENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the…

3 days ago
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 07, 2025 16:05 ET  | Source: Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics,…

6 days ago
Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)

Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)

February 07, 2025 16:01 ET  | Source: Replimune Group Inc WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group,…

6 days ago